Intranasal Covid Vaccine
- All
- News
- Videos
-
3 Lakh Doses Of Intranasal Covid Vaccine Sent To Hospital: Bharat Biotech
Bharat Biotech dispatched three lakh doses of its intranasal COVID-19 vaccine to some hospitals two days ago, the company's executive chairman Krishna Ella said on Sunday.
-
Covid Nasal Vaccine A "Mighty Display Of India's Research: Health Minister
Mansukh Manadaviya said that the world's first intranasal vaccine for Covid-19 iNCOVACC launched is a testimony to the innovative zeal of our scientists and a display of India's research and innovation prowess under the leadership of PM Modi.
-
World's 1st Covid Nasal Vaccine, Made In India, To Be Out On Republic Day
Homegrown vaccine maker Bharat Biotech will launch its intranasal COVID-19 vaccine iNCOVACC, the first of its kind in India, on January 26.
-
India's Intranasal Covid Vaccine Is Here. Can Be Availed On COWIN Platform
Bharat Biotech's intranasal Covid vaccine has been approved by the Union Health Ministry as a booster dose for those aged 18 years and above and is likely to be introduced on the Co-WIN platform Friday evening, official sources said.
-
Nasal Vaccine Available From Today. Where You Can Get It
The government today approved the inclusion of an intranasal Covid vaccine in the vaccination programme as a booster dose for adults. The inclusion comes amid a surge in cases in China and some other countries.
-
Bharat Biotech Asks Centre To List Its Nasal Covid Vaccine On CoWIN Portal: Report
Bharat Biotech has requested the central government to include its intranasal COVID-19 vaccine iNCOVACC, in CoWIN portal to enable the recipients of the jab to get vaccination certificate.
-
Bharat Biotech To Launch 1st Nasal Covid Vaccine, No Efficacy Data Released
Bharat Biotech's needle-free intranasal Covid vaccine has been cleared for restricted use in emergency situations for those above the age of 18 years. iNCOVACC will become the first intranasal vaccine in the world.
-
New Intranasal Anti-Viral Treatment May Block Covid Transmission: Report
Researchers have developed an intranasal anti-viral treatment for COVID-19 that decreases the amount of SARS-CoV-2 shed from infected animals and limits transmission of the virus.
-
Bharat Biotech Says Intranasal Covid Vaccine Found Safe In Booster Trials
Bharat Biotech International Ltd (BBIL) on Monday said it has completed the phase-III and booster dose trials for its intranasal Covid-19 vaccine BBV154, and it has proven to be safe.
-
Bharat Biotech Expects Regulator's Nod For Intranasal Covid Vaccine In Aug
Bharat Biotech, which is working on an intranasal COVID-19 vaccine candidate is hopeful of getting regulatory licenses this month, if all goes well, Chairman and Managing Director of BBIL, Krishna Ella said.
-
Covaxin Maker Bharat Biotech's Nasal Booster Dose Trials Get Approval
Vaccine manufacturer Bharat Biotech has received approval to conduct Phase-III clinical trials of an intranasal booster dose on people who have received both doses of Covaxin.
-
Bharat Biotech Seeks Approval For Phase 3 Trial Of Intranasal Shots As Boosters
Bharat Biotech has sought the Drug Controller General of India's approval to conduct phase-3 trials of its intranasal vaccine (BBV154) against Covid to be used as a booster dose, sources said on Monday.
-
Bharat Biotech's 1st Nasal Covid Vaccine Gets Phase 2/3 Trial Nod
BBV154, developed by Bharat Biotech, is India's first intranasal vaccine to receive regulatory nod for late-stage clinical trials from the Biotechnology Industry Research Assistance Council's (BIRAC) under the Department of Biotechnology.
-
Nasal Covid Vaccine Candidate In Early Stage Of Development: Centre
An intranasal vaccine candidate (BBV154), being developed by Bharat Biotech, is in early clinical stage of development in India, Minister of State for Health Ashwini Choubey told the Rajya Sabha on Tuesday.
-
Bharat Biotech Partners With US University For Single-Dose Covid Vaccine
Hyderabad-based pharma firm Bharat Biotech, which is developing coronavirus vaccine COVAXIN, has signed a licensing deal with Washington University School of Medicine in Missouri's St. Louis, United States, for a "novel chimp-adenovirus", single dose intranasal vaccine for COVID-19. Bharat Biotech would be allowed to distribute the vaccine in all m...
-
3 Lakh Doses Of Intranasal Covid Vaccine Sent To Hospital: Bharat Biotech
Bharat Biotech dispatched three lakh doses of its intranasal COVID-19 vaccine to some hospitals two days ago, the company's executive chairman Krishna Ella said on Sunday.
-
Covid Nasal Vaccine A "Mighty Display Of India's Research: Health Minister
Mansukh Manadaviya said that the world's first intranasal vaccine for Covid-19 iNCOVACC launched is a testimony to the innovative zeal of our scientists and a display of India's research and innovation prowess under the leadership of PM Modi.
-
World's 1st Covid Nasal Vaccine, Made In India, To Be Out On Republic Day
Homegrown vaccine maker Bharat Biotech will launch its intranasal COVID-19 vaccine iNCOVACC, the first of its kind in India, on January 26.
-
India's Intranasal Covid Vaccine Is Here. Can Be Availed On COWIN Platform
Bharat Biotech's intranasal Covid vaccine has been approved by the Union Health Ministry as a booster dose for those aged 18 years and above and is likely to be introduced on the Co-WIN platform Friday evening, official sources said.
-
Nasal Vaccine Available From Today. Where You Can Get It
The government today approved the inclusion of an intranasal Covid vaccine in the vaccination programme as a booster dose for adults. The inclusion comes amid a surge in cases in China and some other countries.
-
Bharat Biotech Asks Centre To List Its Nasal Covid Vaccine On CoWIN Portal: Report
Bharat Biotech has requested the central government to include its intranasal COVID-19 vaccine iNCOVACC, in CoWIN portal to enable the recipients of the jab to get vaccination certificate.
-
Bharat Biotech To Launch 1st Nasal Covid Vaccine, No Efficacy Data Released
Bharat Biotech's needle-free intranasal Covid vaccine has been cleared for restricted use in emergency situations for those above the age of 18 years. iNCOVACC will become the first intranasal vaccine in the world.
-
New Intranasal Anti-Viral Treatment May Block Covid Transmission: Report
Researchers have developed an intranasal anti-viral treatment for COVID-19 that decreases the amount of SARS-CoV-2 shed from infected animals and limits transmission of the virus.
-
Bharat Biotech Says Intranasal Covid Vaccine Found Safe In Booster Trials
Bharat Biotech International Ltd (BBIL) on Monday said it has completed the phase-III and booster dose trials for its intranasal Covid-19 vaccine BBV154, and it has proven to be safe.
-
Bharat Biotech Expects Regulator's Nod For Intranasal Covid Vaccine In Aug
Bharat Biotech, which is working on an intranasal COVID-19 vaccine candidate is hopeful of getting regulatory licenses this month, if all goes well, Chairman and Managing Director of BBIL, Krishna Ella said.
-
Covaxin Maker Bharat Biotech's Nasal Booster Dose Trials Get Approval
Vaccine manufacturer Bharat Biotech has received approval to conduct Phase-III clinical trials of an intranasal booster dose on people who have received both doses of Covaxin.
-
Bharat Biotech Seeks Approval For Phase 3 Trial Of Intranasal Shots As Boosters
Bharat Biotech has sought the Drug Controller General of India's approval to conduct phase-3 trials of its intranasal vaccine (BBV154) against Covid to be used as a booster dose, sources said on Monday.
-
Bharat Biotech's 1st Nasal Covid Vaccine Gets Phase 2/3 Trial Nod
BBV154, developed by Bharat Biotech, is India's first intranasal vaccine to receive regulatory nod for late-stage clinical trials from the Biotechnology Industry Research Assistance Council's (BIRAC) under the Department of Biotechnology.
-
Nasal Covid Vaccine Candidate In Early Stage Of Development: Centre
An intranasal vaccine candidate (BBV154), being developed by Bharat Biotech, is in early clinical stage of development in India, Minister of State for Health Ashwini Choubey told the Rajya Sabha on Tuesday.
-
Bharat Biotech Partners With US University For Single-Dose Covid Vaccine
Hyderabad-based pharma firm Bharat Biotech, which is developing coronavirus vaccine COVAXIN, has signed a licensing deal with Washington University School of Medicine in Missouri's St. Louis, United States, for a "novel chimp-adenovirus", single dose intranasal vaccine for COVID-19. Bharat Biotech would be allowed to distribute the vaccine in all m...
